Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial

Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?

(2014) Philip Home et al.   DIABETES CARE

Predictive and Explanatory Factors of Change in HbA1cin a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs

(2014) Philip D. Home et al.   DIABETES CARE

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

(2014) J. Farngren et al.   DIABETES OBESITY & METABOLISM

Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans

(2014) Monika J Bak et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Effects of Mitiglinide, a Short-Acting Insulin Secretagogue, on Daily Glycemic Variability and Oxidative Stress Markers in Japanese Patients with Type 2 Diabetes Mellitus

(2013) Noriko Kodani et al.   CLINICAL DRUG INVESTIGATION

Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study

(2013) Stewart B. Harris et al.   DIABETES CARE

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes

(2013) Carolina Solis-Herrera et al.   DIABETES CARE

Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and  -Cell Function in TODAY

(2013)   DIABETES CARE

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

(2013) Y. G. Kim et al.   DIABETOLOGIA

Lower beta cell function relates to sustained higher glycated albumin to glycated hemoglobin ratio in Japanese patients with type 2 diabetes

(2013) Yoshifumi Saisho et al.   ENDOCRINE JOURNAL

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

(2013) Steven E Kahn et al.   LANCET

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study

(2013) D. T. Eurich et al.   BMJ-British Medical Journal

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study

(2012) E. S. Hong et al.   DIABETES OBESITY & METABOLISM

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

(2012) K. Gooßen et al.   DIABETES OBESITY & METABOLISM

Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes

(2012) Elza Muscelli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan

(2011) Hitoshi Ishii et al.   CURRENT MEDICAL RESEARCH AND OPINION

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

(2011) Matteo Monami et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of Rosiglitazone, Glyburide, and Metformin on  -Cell Function and Insulin Sensitivity in ADOPT

(2011) S. E. Kahn et al.   DIABETES

Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of

(2011) D. Giugliano et al.   DIABETES CARE

Proportion of patients at HbA1c target

(2011) K. Esposito et al.   DIABETES OBESITY & METABOLISM

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

(2011) Daisuke Yabe et al.   Journal of Diabetes Investigation

Relationship of baseline HbA1cand efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

(2010) R. A. DeFronzo et al.   DIABETIC MEDICINE

Revised Equations for Estimated GFR From Serum Creatinine in Japan

(2009) Seiichi Matsuo et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

 -Cell-Mediated Signaling Predominates Over Direct  -Cell Signaling in the Regulation of Glucagon Secretion in Humans

(2009) B. A. Cooperberg et al.   DIABETES CARE

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

The effects of glucagon-like peptide-1 on the beta cell

(2009) T. Vilsbøll   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

(2009) T. Vilsbøll et al.   DIABETES OBESITY & METABOLISM

Treatment Satisfaction and Quality of Life With Insulin Glargine Plus Insulin Lispro Compared With NPH Insulin Plus Unmodified Human Insulin in Individuals With Type 1 Diabetes

(2008) S. G. Ashwell et al.   DIABETES CARE

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

(2008) J. de Heer et al.   DIABETOLOGIA